SEC Comment Letter 0000000000-24-000502 to Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc.
Date: Jan. 16, 2024 · CIK: 0000890821 · Accession: 0000000000-24-000502
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276473
Letter
United States securities and exchange commission logo January 16, 2024 Joseph Tucker Chief Executive Officer Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, FL 34103 Re:Enveric Biosciences, Inc. Registration Statement on Form S-3 Filed January 11, 2024 File No. 333-276473 Dear Joseph Tucker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Adin J. Tarr, Esq.
Show Raw Text
United States securities and exchange commission logo
January 16, 2024
Joseph Tucker
Chief Executive Officer
Enveric Biosciences, Inc.
4851 Tamiami Trail N, Suite 200
Naples, FL 34103
Re:Enveric Biosciences, Inc.
Registration Statement on Form S-3
Filed January 11, 2024
File No. 333-276473
Dear Joseph Tucker:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Adin J. Tarr, Esq.